Cowen and Company’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Cowen and Company’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,369	Closed	-$20.6K	–	290
2024 Q3	$20.6K	Hold	20,369	–	–	﹤0.01%	428
2024 Q2	$33.2K	Sell	20,369 -30,055	-60%	-$40.8K	﹤0.01%	350
2024 Q1	$50.4K	Buy	+50,424	New	+$50.3K	﹤0.01%	348
2021 Q3	–	Sell	-27,500	Closed	-$28K	–	700
2021 Q2	$28K	Buy	27,500 +4,060	+17%	+$4.01K	﹤0.01%	456
2021 Q1	$26K	Buy	+23,440	New	+$42.3K	﹤0.01%	439

Other funds holding TLSIW

Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return

ACM

Alpha Capital Management Austin, Texas $690M AUM 22.82% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

FVWA

Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cowen and Company's TLSIW Position: Q4 2024 in Review

Cowen and Company sold out of TriSalus Life Sciences Warrant (TLSIW) in Q4 2024, closing a stake of 20,369 shares — an estimated $20.6K sold.

Cowen and Company first reported a position in TLSIW in Q1 2021 and held it in 5 quarters. The position peaked at $50.4K in Q1 2024. 8 funds tracked by Wall St. Rank hold TLSIW as of Q4 2024.

Cowen and Company reported no remaining TriSalus Life Sciences Warrant position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 20,369 TriSalus Life Sciences Warrant shares in Q4 2024, an estimated $20.6K.
Cowen and Company first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and held it in 5 quarters.
Cowen and Company's TriSalus Life Sciences Warrant position peaked at $50.4K in Q1 2024.
8 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.